Evaluation of the efficacy and safety of original filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and LENOGRASTIM (cas 135968-09-1) (Granocyte®) in CD34+ peripheral hematopoietic stem cell mobilization procedures for allogeneic hematopoietic stem cell transplant donors

Add time:08/21/2019    Source:sciencedirect.com

Objectives and AimIn this study, we aimed to compare the potency of different G-CSF agents including original filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and LENOGRASTIM (cas 135968-09-1) (Granocyte®) on CD34+ cell mobilization in patients that underwent allogeneic hematopoietic stem cell transplantation (alloHSCT).

We also recommend Trading Suppliers and Manufacturers of LENOGRASTIM (cas 135968-09-1). Pls Click Website Link as below: cas 135968-09-1 suppliers

Prev:Original ArticleBiosimilar filgrastim (leucostim®) have similar efficacy in steady-state hematopoietic progenitor cell mobilization compared to original filgrastim (neupogen®) and LENOGRASTIM (cas 135968-09-1) (granocyte®): A retrospective multicenter study
Next:Clinical—LiverAmino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to Sofosbuvir)